Page 27 - Discover Top Biotechnology Partners From Poland - Business Catalogue

Polish Biotechnology Sector Polish Biotechnology Sector

COMPANY NAME: Molecule One Sp. z o.o. COMPANY NAME: MOLECURE S.A.

WEBSITE : https://www.molecule.one/ WEBSITE : https://www.molecure.com
YEAR OF ESTABLISHMENT: 2016 YEAR OF ESTABLISHMENT: 2012
NUMBER OF EMPLOYEES: 23 NUMBER OF EMPLOYEES: 109
CERTIFICATIONS: - CERTIFICATIONS:

PRODUCTS: RetroM1 - retrosynthesis pathway planner; RetroSAS - Synthetic PRODUCTS: Small molecules; Small molecules targeting mRNA ; First in class and
Accessibility Scoring tool; CouplingM1 - reaction conditions best in class drugs; Chitinase inhibitors; Inflammatory fibrotic diseases;
recommendation tool; High Throughput Laboratory Data; Custom Sarcoidosis; Dual arginase inhibitors; Immuno-oncology; Deubiquitinase
Laboratory solutions; inhibitors; Phase 1 and phase 2 programs; Macrophages and T cell
modifiers
FORM OF COOPERATION: Trade and distribution FORM OF COOPERATION: Investment

Molecure is a clinical stage biotechnology company
discovering and developing first-in-class small molecule
Molecule.one is an AI-driven biotech company enhancing
drug candidates that directly modulate underexplored
drug discovery with predictive chemistry systems. Using
protein targets and the function of RNA to treat multiple
deep learning and data from our high-throughput
incurable diseases. We have generated a diverse pipeline of
chemistry laboratory, we create tools that simplify chemical
7 distinct programs with the support of leading academic
synthesis planning. Our services boost chemist’s efficiency
life science institutions globally. Our most advanced in-
with retrosynthesis prediction, reaction condition
house drug candidate is OATD-01, a Ph2 chitinase inhibitor
suggestions, and synthesis feasibility assessments of
for the treatment of sarcoidosis and other ILDs. OATD-02,
compound libraries. Our diverse team of chemistry, IT and
our second proprietary candidate, is an oral, potent and
machine learning experts ensures we consistently provide
selective dual arginase inhibitor (ARG1/2) in Ph1 for the
high-quality solutions to chemists worldwide.
treatment of cancer. We also explore DUBs and develop
mRNA platform.